Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H28O2 |
Molar mass | 300.442 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Δ9-Tetrahydrocannabutol (tetrahydrocannabinol-C4, THC-C4, Δ9-THCB, (C4)-Δ9-THC, butyl-THC) is a homologue of tetrahydrocannabinol (THC), the active component of cannabis.[1] They are only different by the pentyl side chain being replaced by a butyl side chain. Δ9-THCB, showed an affinity for the human CB1 (Ki = 15 nM) and CB2 receptors (Ki = 51 nM) comparable to that of Δ9-THC.[1] The formalin test in vivo was performed on Δ9-THCB in order to reveal possible analgesic and anti-inflammatory properties.[1] The tetrad test in mice showed a partial agonistic activity of Δ9-THCB toward the CB1 receptor.[1] The propyl analog, THCV, is a cannabinoid receptor type 1 and cannabinoid receptor type 2 antagonist,[2] while THC is a CB1 agonist. THCB has rarely been isolated from cannabis samples,[1][3] but appears to be less commonly present than THC or THCV. It is metabolised in a similar manner to THC.[4] Similarly to THC, it has 7 double bond isomers and 30 stereoisomers.[5] The Δ8 isomer is known as a synthetic cannabinoid under the code name JWH-130,[6] and the ring-opened analogue cannibidibutol is also known.[7]
THCB is not scheduled internationally under the Convention on Psychotropic Substances, but may be controlled under analogue law in some individual jurisdictions as a homologue of THC.